John Doerr, chairman of Kleiner Perkins, is one of the most influential venture capitalists in Silicon Valley, backing industry-defining companies that helped shape the modern internet and clean-tech revolutions. Since joining the firm in 1980 after a successful career at Intel, he led investments in Amazon, Google, Netscape, Sun Microsystems, and later climate-focused innovators such as Beyond Meat and QuantumScape. Doerr is also a leading voice for mission-driven entrepreneurship, championing OKR management frameworks and ambitious climate policy through philanthropy and his book Speed & Scale. His decades-long impact continues to steer technology, leadership, and climate innovation on a global scale.

George Yancopoulos, cofounder, president, and chief scientific officer of Regeneron Pharmaceuticals, is one of the most accomplished scientist-executives in biotechnology. A Columbia-trained physician and molecular immunologist, he helped shape Regeneron’s R&D engine, leading to breakthrough therapies in ophthalmology, immunology, oncology, and infectious disease. Under his guidance, the company developed Eylea, a blockbuster treatment for macular degeneration, and partnered in creating COVID-19 antibody therapies. With hundreds of patents and a reputation for scientific rigor, Yancopoulos has become a driving force behind Regeneron’s rise as a global biotech leader.

Charles R. Schwab is the pioneering founder, longtime CEO, and current Co‑Chairman of The Charles Schwab Corporation, which he started in 1971. Renowned for revolutionizing the discount brokerage industry—offering low-cost, tech-driven trading and eliminating commissions—he built one of the largest global investment firms managing over $10 trillion in client assets and serving more than 32 million accounts. Semi-retiring in 2008, he remains the largest individual shareholder and leads the Schwab Foundation’s education and dyslexia initiatives.